Skip to main content
SpringerLink
Log in

Intra-abdominal adiposity, inflammation, and cardiovascular risk: New insight into global cardiometabolic risk

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Increasing evidence supports the role of adipose tissue in the development of a systemic inflammatory state, which contributes to obesity-associated vasculopathy and cardiovascular risk. In addition to storing calories as triglycerides, adipocytes secrete a large variety of proteins, including cytokines, chemokines, and hormone-like factors (eg, leptin, adiponectin, resistin). This production of pro chemokines by adipose tissue is of particular interest, because their local secretion by perivascular adipose depots may provide a new mechanistic link between obesity and its associated vascular complications. Insulin resistance, in subjects with or without diabetes, is frequently associated with obesity, particularly with an excess of intra-abdominal fat. Recently, the endocannabinoid system, among others, has been shown to be involved in the pathophysiology of visceral obesity and global cardiometabolic risk, as represented by the overall risk of developing type 2 diabetes or cardiovascular diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548–2556.

    Article  PubMed  CAS  Google Scholar 

  2. Peelman F, Waelput W, Iserentant H, et al.: Leptin: linking adipocyte metabolism with cardiovascular and autoimmune diseases. Prog Lipid Res 2004, 43:283–301.

    Article  PubMed  CAS  Google Scholar 

  3. Yudkin JS, Kumari M, Humphries SE: Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000, 148:209–214.

    Article  PubMed  CAS  Google Scholar 

  4. Rennie KL, Jebb SA: Prevalence of obesity in Great Britain. Obes Rev 2005, 6:11–12.

    Article  PubMed  CAS  Google Scholar 

  5. Engstrom G, Stavenow L, Hedblad B, et al.: Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. Diabetes 2003, 52:442–447.

    Article  PubMed  CAS  Google Scholar 

  6. Calabro P, Yeh ET: Inflammatory vascular markers in atherosclerosis. In Current Topics in Atherosclerosis Research. Edited by Geng YJ. Hauppauge: Nova Science Publishers; 2005:49–65.

    Google Scholar 

  7. Yudkin JS: Adipose tissue, insulin action and vascular disease: inflammatory signals. Int J Obes Relat Metab Disord 2003, 27(Suppl 3):S25–S28.

    Article  PubMed  CAS  Google Scholar 

  8. Calabro P, Willerson JT, Yeh ET: Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003, 108:1930–1932.

    Article  PubMed  CAS  Google Scholar 

  9. Calabro P, Chang DW, Willerson JT, Yeh ET: Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. J Am Coll Cardiol 2005, 46:1112–1113.

    Article  PubMed  CAS  Google Scholar 

  10. Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.

    Article  PubMed  CAS  Google Scholar 

  11. Calabro P, Chang DW, Willerson JT, Yeh ET: Production of C-reactive protein and serum amyloid A in response to inflammatory cytokines by human adipocytes. Eur H Journal 2005, 26(Suppl):334–335.

    Google Scholar 

  12. Ouchi N, Kihara S, Arita Y, et al.: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296–1301.

    PubMed  CAS  Google Scholar 

  13. Ahima RS, Flier JS: Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000, 11:327–332.

    Article  PubMed  CAS  Google Scholar 

  14. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999, 19:972–978.

    PubMed  CAS  Google Scholar 

  15. Itoh K, Imai K, Masuda T, et al.: Relationship between changes in serum leptin levels and blood pressure after weight loss. Hypertens Res 2002, 25:881–886.

    Article  PubMed  CAS  Google Scholar 

  16. De Pergola G, Pannacciulli N: Coagulation and fibrinolysis abnormalities in obesity. J Endocrinol Invest 2002, 25:899–904.

    PubMed  Google Scholar 

  17. Sartipy P, Loskutoff DJ: Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 2003, 100:7265–7270.

    Article  PubMed  CAS  Google Scholar 

  18. Weyer C, Yudkin JS, Stehouwer CD, et al.: Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002, 161:233–242.

    Article  PubMed  CAS  Google Scholar 

  19. Xu H, Barnes GT, Yang Q, et al.: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821–1830.

    Article  PubMed  CAS  Google Scholar 

  20. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745–E751.

    PubMed  CAS  Google Scholar 

  21. Mohamed-Ali V, Goodrick S, Rawesh A, et al.: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997, 82:4196–4200.

    Article  PubMed  CAS  Google Scholar 

  22. Pradhan AD, Manson JE, Rifai N, et al.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327–334.

    Article  PubMed  CAS  Google Scholar 

  23. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767–72.

    PubMed  CAS  Google Scholar 

  24. Halaas JL, Gajiwala KS, Maffei M, et al.: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269:543–546.

    Article  PubMed  CAS  Google Scholar 

  25. Oral EA, Simha V, Ruiz E, et al.: Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002, 346:570–578.

    Article  PubMed  CAS  Google Scholar 

  26. Steppan CM, Bailey ST, Bhat S, et al.: The hormone resistin links obesity to diabetes. Nature 2001, 409:307–312.

    Article  PubMed  CAS  Google Scholar 

  27. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al.: Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88:5452–5455.

    Article  PubMed  CAS  Google Scholar 

  28. Patel L, Buckels AC, Kinghorn IJ, et al.: Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003, 300:472–476.

    Article  PubMed  CAS  Google Scholar 

  29. Verma S, Li SH, Wang CH, et al.: Resistin promotes endothelial cell activation: further evidence of adipokineendothelial interaction. Circulation 2003, 108:736–740. [Published erratum appears in Circulation 2004, 109:2254.]

    Article  PubMed  CAS  Google Scholar 

  30. Calabro P, Samudio I, Willerson JT, Yeh ET: Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004, 110:3335–3340.

    Article  PubMed  CAS  Google Scholar 

  31. Burnett MS, Lee CW, Kinnaird TD, et al.: The potential role of resistin in atherogenesis. Atherosclerosis 2005, 182:241–248.

    Article  PubMed  CAS  Google Scholar 

  32. Lee JH, Bullen JW Jr, Stoyneva VL, Mantzoros CS: Circulating resistin in lean, obese, and insulin-resistant mouse models: lack of association with insulinemia and glycemia. Am J Physiol Endocrinol Metab 2005, 288:E625–E632.

    Article  PubMed  CAS  Google Scholar 

  33. Vendrell J, Broch M, Vilarrasa N, et al.: Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res 2004, 12:962–971.

    Article  PubMed  CAS  Google Scholar 

  34. Fruebis J, Tsao TS, Javorschi S, et al.: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 2001, 98:2005–2010.

    Article  PubMed  CAS  Google Scholar 

  35. Pischon T, Girman CJ, Hotamisligil GS, et al.: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730–1737.

    Article  PubMed  CAS  Google Scholar 

  36. Hotta K, Funahashi T, Bodkin NL, et al.: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001, 50:1126–1133.

    Article  PubMed  CAS  Google Scholar 

  37. Ouchi N, Kihara S, Arita Y, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473–2476.

    PubMed  CAS  Google Scholar 

  38. Ouchi N, Kihara S, Arita Y, et al.: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057–1063.

    PubMed  CAS  Google Scholar 

  39. Kumada M, Kihara S, Ouchi N, et al.: Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation 2004, 109:2046–2049.

    Article  PubMed  CAS  Google Scholar 

  40. Chen H, Montagnani M, Funahashi T, et al.: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003, 278:45021–45026.

    Article  PubMed  CAS  Google Scholar 

  41. Kawanami D, Maemura K, Takeda N, et al.: Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 2004, 314:415–419.

    Article  PubMed  CAS  Google Scholar 

  42. Ouchi N, Kobayashi H, Kihara S, et al.: Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004, 279:1304–1309.

    Article  PubMed  CAS  Google Scholar 

  43. Boden G, Zhange M: Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin Investig Drugs 2006, 15:243–250.

    Article  PubMed  CAS  Google Scholar 

  44. Brekke HK, Lenner RA, Taskinen MR, et al.: Lifestyle modification improves risk factors in type 2 diabetes relatives. Diabetes Res Clin Pract 2005, 68:18–28.

    Article  PubMed  Google Scholar 

  45. Koh KK, Quon MJ, Han SH, et al.: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110:3687–3692.

    Article  PubMed  CAS  Google Scholar 

  46. Koh KK, Han SH, Quon MJ: Beneficial effects of feno-fibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005, 28:1419–1424.

    Article  PubMed  CAS  Google Scholar 

  47. Ridker PM, Koenig W, Fuster V: C-reactive protein and coronary heart disease. N Engl J Med 2004, 351:295–298; author reply 295–298.

    Article  PubMed  Google Scholar 

  48. Calabro P, Willerson JT, Yeh ET. Inflammation, C-reactive protein, and vulnerable plaque. In Cardiovascular Medicine. Edited by Willerson JT, Cohn JN, Wellens HJJ, Holmes DR. New York: Springer; 2007:611–618.

    Chapter  Google Scholar 

  49. Esposito K, Pontillo A, Di Palo C, et al.: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289:1799–1804.

    Article  PubMed  CAS  Google Scholar 

  50. Esposito K, Marfella R, Ciotola M, et al.: Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004, 292:1440–1446.

    Article  PubMed  CAS  Google Scholar 

  51. Okita K, Nishijima H, Murakami T, et al.: Can exercise training with weight loss lower serum C-reactive protein levels? Arterioscler Thromb Vasc Biol 2004, 24:1868–1873.

    Article  PubMed  CAS  Google Scholar 

  52. Ouchi N, Kihara S, Funahashi T, et al.: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 2003, 107:671–674.

    Article  PubMed  CAS  Google Scholar 

  53. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836–843.

    Article  PubMed  CAS  Google Scholar 

  54. Trayhurn P, Wood IS: Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004, 92:347–355.

    Article  PubMed  CAS  Google Scholar 

  55. Calabro P, Samudio I, Safe SH, et al.: Inhibition of tumornecrosis-factor-alpha induced endothelial cell activation by a new class of PPAR-gamma agonists. An in vitro study showing receptor-independent effects. J Vasc Res 2005, 42:509–516.

    Article  PubMed  CAS  Google Scholar 

  56. Haffner SM, Greenberg AS, Weston WM, et al.: Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002, 106:679–684.

    Article  PubMed  CAS  Google Scholar 

  57. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al.: Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004, 53:2169–2176.

    Article  PubMed  CAS  Google Scholar 

  58. Pagotto U, Pasquali R: Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet 2005, 365:1363–1364.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Cardiothoracic Sciences, Second University of Naples, Naples, Italy

    Paolo Calabro

Authors
  1. Paolo Calabro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Edward T. H. Yeh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Calabro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Calabro, P., Yeh, E.T.H. Intra-abdominal adiposity, inflammation, and cardiovascular risk: New insight into global cardiometabolic risk. Current Science Inc 10, 32–38 (2008). https://doi.org/10.1007/s11906-008-0008-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-008-0008-z

Keywords

Search

Navigation